Skip to main content

Table 4 Characteristics and outcome in patients who discontinued G/P treatment

From: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

No.

Age

Gender

GT

Liver status

AEs

Treatment duration (weeks)

Outcome

 

1

62

M

1b

LC

Pruritus

Headache

Dyspnea

2

SVR

After the discontinuation of G/P treatment, changing to LDV/SOF

2

63

M

2

CH

Elevation of ALT

6

SVR

 

3

72

F

2a

CH

Headache

Cold-like symptoms

4

SVR

 

4

54

F

2b

LC

Elevation of Total bilirubin

8

SVR

 

5

70

F

2

CH

Elevation of ALT

7

Non-response

 
  1. M, male; F, female; GT, genotype; LC, liver cirrhosis; CH, chronic hepatitis; AEs, adverse events; ALT, alanine aminotransferase; G/P, glecaprevir/pibrentasuvir; LDV, ledipasvir; SOF, sofosbuvir